Survival of Brucella abortus strain RB51 lyophilized and as liquid vaccine under different storage conditions.

Abstract Brucella abortus strain RB51 (SRB51) is a new cattle vaccine that is approved for use in the U.S. for prevention of brucellosis. At the present time, other countries are implementing or considering the use of SRB51 vaccine in their brucellosis control programs. In the current study, the effect of three stabilizing media, two fill volumes (1 and 3 ml), and three storage temperatures (−25, 4 and 25°C) on the viability of lyophilized SRB51 over a 52 week period was determined. The effects of three concentrations of bacteria (5×10 8 , 1×10 9 , or 5×10 9  cfu/ml) and two storage temperatures (4 or 25°C) on viability of liquid SRB51 vaccine were also determined. For lyophilized strain RB51 vaccine, fill volume did not influence viability ( P> 0·05) during lyophilization. Although fill volume did not influence viability during storage in World Health Organization (WHO) media or media containing both WHO and Lactose Salt (LS) media, 1 ml fill volumes of SRB51 in LS media had greater ( P 0·05) viability when compared to 3 ml fill volumes. Lyophilized SRB51 vaccine stored at 25°C had a more rapid decline in viability ( P 0·05) when compared to vaccine stored at −25 or 4°C. With the exception of the 3-ml fill volumes of LS media, all three stabilizing media were similar in maintaining viability of SRB51 at −25°C storage temperatures. However, when compared to WHO or WHO/LS media, stabilization in LS media was associated with a more rapid decline in viability during storage at 4 or 25°C ( P 0·05). Initial SRB51 concentration in liquid vaccine did not influence ( P> 0·05) viability during storage at 4 or 25°C. When compared to liquid SRB51 vaccine stored at 25°C, storage at 4°C was associated with a slower decline in viability ( P 0·05) during 12 weeks of storage. Biochemical and morphological characteristics of SRB51 were stable under the storage conditions utilized in the present study. This study suggests that viability of SRB51 can be readily maintained during storage as a lyophilized or liquid brucellosis vaccine.